AbbVie (ABBV) Amortizatization of Intangibles (2012 - 2026)
AbbVie (ABBV) posted quarterly Amortizatization of Intangibles of $1.7 billion for Q1 2026, down 8.5% YoY from $1.9 billion in Q1 2025, and down 4.33% sequentially from $1.8 billion in Q4 2025.
AbbVie (ABBV) Amortizatization of Intangibles (2012 - 2026) Analysis & Trends
AbbVie has disclosed Amortizatization of Intangibles across 15 years of filings, most recently posting $1.7 billion for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 8.5% year-over-year to $1.7 billion; the TTM figure through Mar 2026 stood at $7.3 billion (down 3.39% YoY), while the FY2025 annual figure was $7.4 billion, down 2.93% from the prior year.
- Amortizatization of Intangibles eased to $1.7 billion in Q1 2026, from $1.8 billion in the prior quarter.
- Over the last five years, Amortizatization of Intangibles for ABBV reached as high as $2.1 billion in Q2 2023 and fell as low as $1.7 billion in Q1 2026.
- The 5-year median for Amortizatization of Intangibles is $1.9 billion (2024), against an average of $1.9 billion.
- Annual changes were most pronounced in 2022 — Amortizatization of Intangibles slipped 10.0% — and 2023, when it rose 16.67%.
- A 5-year view of Amortizatization of Intangibles shows it stood at $2.0 billion in 2022, then decreased by 7.85% to $1.8 billion in 2023, then increased by 1.68% to $1.9 billion in 2024, then dropped by 5.18% to $1.8 billion in 2025, then dropped by 4.33% to $1.7 billion in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $1.7 billion, $1.8 billion, and $1.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amort. of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 1.70 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 931.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 596.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 107.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.70 Bn |
| Mar 31, 2026 | 1.70 Bn |
| Dec 31, 2025 | 1.78 Bn |
| Dec 31, 2025 | 1.78 Bn |
| Sep 30, 2025 | 1.90 Bn |
| Sep 30, 2025 | 1.90 Bn |
| Jun 30, 2025 | 1.90 Bn |
| Jun 30, 2025 | 1.90 Bn |
| Mar 31, 2025 | 1.86 Bn |
| Mar 31, 2025 | 1.86 Bn |
| Dec 31, 2024 | 1.87 Bn |
| Dec 31, 2024 | 1.87 Bn |
| Sep 30, 2024 | 1.90 Bn |
| Sep 30, 2024 | 1.90 Bn |
| Jun 30, 2024 | 1.90 Bn |
| Jun 30, 2024 | 1.90 Bn |
| Mar 31, 2024 | 1.90 Bn |
| Mar 31, 2024 | 1.90 Bn |
| Dec 31, 2023 | 1.84 Bn |
| Dec 31, 2023 | 1.84 Bn |